文献速递肝肾功能剂量调整特殊人群用药药物相互作用

埃格列净临床药理学综述:一种新型SGLT2抑制剂

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
PubMed 文献 · Clin Pharmacokinet · 2020-01-01

本文综述埃格列净I期临床开发中的药代动力学与药效学数据,支持其注册与说明书制定。埃格列净口服吸收迅速,半衰期11-18小时,暴露量呈剂量比例增加,食物无临床相关影响。轻至重度肾功能不全无需调整剂量,中度肝功能不全AUC降低13%无临床意义。与二甲双胍、西格列汀、格列美脲或辛伐他汀合用无临床显著相互作用。

要点

  • 埃格列净可不受进食状态给药,无需考虑餐时。
  • 轻至重度肾功能不全患者无需调整剂量。
  • 与常用药物合用无需调整剂量,利福平降低AUC 39%但预期不影响疗效。

核心结论

  • 埃格列净的药代动力学特征支持其用于2型糖尿病成人患者,无需考虑进食状态。
  • 肾功能不全及轻至中度肝功能不全患者无需基于药代动力学调整剂量。
  • 与常见处方药合用无需调整剂量。

研究设计与样本

  • 综述总结埃格列净I期临床开发中获得的药代动力学和药效学数据。

主要发现

  • 健康受试者与2型糖尿病患者中药代动力学相似。
  • 口服吸收迅速,空腹Tmax为1小时,进食后Tmax为2小时。
  • 终末相半衰期为11至18小时,每日一次给药后6天达稳态。
  • 在0.5-300 mg剂量范围内暴露量呈剂量比例增加。
  • 空腹条件下绝对生物利用度约为100%,属BCS I类。

关键数值与推荐

  • 与食物同服15 mg商业片剂对AUC无有意义影响,但Cmax降低29%。
  • 轻、中、重度肾功能不全者埃格列净暴露量较肾功能正常者增加≤70%。
  • 中度肝功能不全者AUC较肝功能正常者降低13%。
  • 利福平合用使埃格列净AUC和Cmax分别降低39%和15%。
  • 与二甲双胍、西格列汀、格列美脲或辛伐他汀合用对埃格列净或合用药物药代动力学无临床意义影响。

临床怎么用

  • 埃格列净可不受进食状态给药。
  • 轻至重度肾功能不全患者无需调整剂量。
  • 轻至中度肝功能不全患者无需调整剂量。
  • 与二甲双胍、西格列汀、格列美脲、辛伐他汀或利福平合用无需调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ertugliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), is approved in the US, EU, and other regions for the treatment of adults with type 2 diabetes mellitus (T2DM). This review summarizes the ertugliflozin pharmacokinetic (PK) and pharmacodynamic data obtained during phase I clinical development, which supported the registration and labeling of this drug. The PK of ertugliflozin was similar in healthy subjects and patients with T2DM. Oral absorption was rapid, with time to peak plasma concentrations (Tmax) occurring at 1 h (fasted) and 2 h (fed) postdose. The terminal phase half-life ranged from 11 to 18 h and steady-state concentrations were achieved by 6 days after initiating once-daily dosing. Ertugliflozin exposure increased in a dose-proportional manner over the tested dose range of 0.5-300 mg. Ertugliflozin is categorized as a Biopharmaceutical Classification System Class I drug with an absolute bioavailability of ~ 100% under fasted conditions. Administration of the ertugliflozin 15 mg commercial tablet with food resulted in no meaningful effect on ertugliflozin area under the plasma concentration-time curve (AUC), but decreased peak concentrations (Cmax) by 29%. The effect on Cmax is not clinically relevant and ertugliflozin can be administered without regard to food. Mild, moderate, and severe renal impairment were associated with a ≤ 70% increase in ertugliflozin exposure relative to subjects with normal renal function, and no dose adjustment in renal impairment patients is needed based on PK results. Consistent with the mechanism of action of SGLT2 inhibitors, 24-h urinary glucose excretion decreased with worsening renal function. In subjects with moderate hepatic impairment, a decrease in AUC (13%) relative to subjects with normal hepatic function was observed and not considered clinically relevant. Concomitant administration of metformin, sitagliptin, glimepiride, or simvastatin with ertugliflozin did not have clinically meaningful effects on the PK of ertugliflozin or the coadministered medications. Coadministration of rifampin decreased ertugliflozin AUC and Cmax by 39% and 15%, respectively, and is not expected to affect efficacy in a clinically meaningful manner. This comprehensive evaluation supports administration to patients with T2DM without regard to prandial status and with no dose adjustments for coadministration with commonly prescribed drugs, or in patients with renal impairment or mild-to-moderate hepatic impairment based on ertugliflozin PK.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Fediuk DJ, Nucci G, Dawra VK, et al. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. Clin Pharmacokinet. 2020. PMID: 32337660. doi:10.1007/s40262-020-00875-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。